Skip to main content
SpringerLink
Log in

Chemotherapy for advanced or recurrent carcinoma of the cervix

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

The management of early-stage cervical cancer involves primarily surgery and/or chemoradiotherapy. When the disease spreads beyond the cervix but remains confined to the pelvis and draining lymph node basins, the mainstay of management is chemoradiotherapy. The use of primary systemic chemotherapy is related to the management of disease that has recurred or spread beyond the pelvic radiation fields. Although the optimal chemotherapy regimen remains to be determined, current protocols and the associated research to support their use are discussed in this review. Additionally, the rationale for use of chemoradiotherapy in locally advanced disease is presented.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics 2000. CA Cancer J Clin, 50:7–33.

  2. Parkin DM, Pisani P, Ferlay J: Estimates of the world wide incidence of eighteen major cancers in 1985. Int J Cancer 1993, 54:594–606.

    Article  PubMed  CAS  Google Scholar 

  3. DiSaia PJ, Creasman WT: Clinical Gynecologic Oncology, edn 5. St. Louis, MO: Mosby; 1997.

    Google Scholar 

  4. DeVita VT Jr, Wasserman T, Young RC, et al.: Perspectives and research in gynecologic oncology. Cancer 1976, 38:509–525.

    Article  PubMed  Google Scholar 

  5. Keys HM, Bundy BN, Stehman FB, et al.: Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999, 340:1154–1161. This prospective, randomized study documents a significant improvement in survival for women with large-volume, early-stage cervical cancer who receive preoperative chemoradiotherapy over preoperative radiotherapy alone prior to hysterectomy.

    Article  PubMed  CAS  Google Scholar 

  6. Rose PG, Bundy BN, Watkins EB, et al.: Concurrent cisplatinbased radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999, 340:1144–1153. Report from the first nationally conducted multicenter clinical trial to confirm the benefits of chemoradiotherapy in the treatment of cancer of the uterine cervix.

    Article  PubMed  CAS  Google Scholar 

  7. Morris M, Eifel PJ, Lu J, et al.: Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999, 340:1137–1143. In a similar manner to the GOG trials of chemoradiotherapy, this RTOG study proved the survival benefits of chemoradiotherapy over radiotherapy alone in advanced cervical cancer. This multi-institution, phase III clinical trial utilized higher radiation dose intensities and treated a wider field in the radiation-only group. Despite these differences in radiation techniques, chemoradiotherapy remained superior to radiation treatment alone.

    Article  PubMed  CAS  Google Scholar 

  8. Whitney CW, Sause W, Bundy BN, et al.: Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999 17:1339–1348. This is the largest multicenter cooperative phase III trial conducted to study the merits of chemoradiotherapy in advanced cervical cancer. This trial confirmed the significant survival advantage to patients receiving combination treatment with concurrent chemotherapy and radiotherapy.

    PubMed  CAS  Google Scholar 

  9. Petters WA III, Lui PY, Barrett R, et al.: Cisplatin, 5-fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive therapy in high-risk, early stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectom: report of a phase III Intergroup Study. Proc Annu Soc Gynecol Oncol 1999, 30. This GOG trial demonstrated a significant survival advantage for women receiving concurrent chemoradiotherapy.

  10. Thigpen JT. Single agent chemotherapy in carcinoma of the cervix. In Cervix Cancer. Edited by Surwit E, Alberts D. Boston: Martinus Nijhoff; 1987:119–136.

    Google Scholar 

  11. Thigpen T: Chemotherapy in the management of advanced or recurrent carcinoma of the cervix. In Cervical Cancer and Preinvasive Neoplasia. Edited by Rubin S, Hoskins W. Philadelphia: Lippincott-Raven; 1996:785–858.

    Google Scholar 

  12. Muscato MS, Perry MC, Yarbro JW: Chemotherapy of cervical carcinoma. Semin Oncol 1982, 9:373–387.

    PubMed  CAS  Google Scholar 

  13. Thigpen T, Vance RB, Balducci L, Blessing J: Chemotherapy in the management of advanced or recurrent cervical and endometrial carcinoma. Cancer 1981, 48:658–665.

    Article  PubMed  CAS  Google Scholar 

  14. Hreshchyshyn M, Aron B, Boronow R, et al.: Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis. Int J Radiat Oncol Biol Phys 1979, 5:317–322.

    PubMed  CAS  Google Scholar 

  15. Steel GG, Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 1979, 5:85–91.

    PubMed  CAS  Google Scholar 

  16. Sinclair WK: The combined effect of hydroxyurea and x-rays on Chinese hamster cells in vitro. Cancer Res 1968, 28:198–206.

    PubMed  CAS  Google Scholar 

  17. Phillips RA, Tolmach LJ: Repair of potentially lethal damage in x-irradiated HeLa cells. Radiat Res 1966, 29:413–432.

    Article  PubMed  CAS  Google Scholar 

  18. Fu KK: Biological basis for the interaction of chemotherapeutic agents and radiation therapy. Cancer 1985, 55(suppl 2):2123–2230.

    Article  PubMed  CAS  Google Scholar 

  19. Bloss, JD, Lucci JA III, DiSaia PJ, et al.: A phase II trial of neoadjuvant chemotherapy prior to radical hysterectomy and/or radiation therapy in the management of advanced carcinoma of the uterine cervix. Gynecol Oncol 1995, 59:105–110.

    Article  PubMed  CAS  Google Scholar 

  20. Thigpen JT, Blessing JA, Fowler WC Jr, Hatch K: Phase II trials of cisplatin and piperazinedione as single agents in the treatment of advanced or recurrent non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Cancer Treat Rep 1986, 70:1097–1100.

    PubMed  CAS  Google Scholar 

  21. Stehman FB, Blessing JA, McGehee R, Barrett RJ: A phase II evaluation of mitolactol in patients with advanced squamouos cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1989, 7:1892–1895.

    PubMed  CAS  Google Scholar 

  22. Lira-Puerto V, Piccart M, Wiernik P, et al.: A comparison of US and Mexican experience with single drug therapy in advanced cervical cancer (NCI-PAH and ECOG study) [abstract]. Proc ASCO 1985, 4:117.

    Google Scholar 

  23. Stehman FB, Blom J, Blessing JA, et al.: Phase II trial of galactitol 1,2:5,7-dianhydro in the treatment of advanced gynecologic malignancies: a Gynecologic Oncology Group Study. Gynecol Oncol 1983, 15:381–390.

    Article  PubMed  CAS  Google Scholar 

  24. Sutton GP, Blessing JA, Photopoulos G, et al.: Phase II experience with ifosfamide/mesna in patients with previously-treated carcinoma of the cervix: a Gynecologic Oncology Group study. Semin Oncol 1989, 16(suppl 3):68–72.

    PubMed  CAS  Google Scholar 

  25. Sutton GP, Blessing JA, Photopoulos G, et al.: Phase II experience with ifosfamide/mesna in patients with previously-treated carcinoma of the cervix: a Gynecologic Oncology Group study. Invest New Drugs 1989, 7:341–343.

    Article  PubMed  CAS  Google Scholar 

  26. Thigpen T, Vance R, Khansur T, Malamud F: The role of ifosfamide and of systemic therapy in the management of carcinoma of the cervix. Semin Oncol 1996, 23(suppl 6):53–64.

    Google Scholar 

  27. Arseneau J, Blessing J, Stehman F, McGehee R: A phase II study of carboplatin in advanced squamous cell carcinoma of the cervix. Invest New Drugs 1986, 4:187–191.

    PubMed  CAS  Google Scholar 

  28. McGuire WP, Arseneau J, Blessing JA, et al.: A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 1989, 7:1462–1468.

    PubMed  Google Scholar 

  29. Thigpen T, Shingleton H, Homesley H, et al.: Cisplatinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix. Cancer 1981, 48:899–903.

    Article  PubMed  CAS  Google Scholar 

  30. Bonomi P, Blessing J, Stehman F, et al.: Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1985, 3:1079–1085.

    PubMed  CAS  Google Scholar 

  31. Thigpen JT, Blessing JA, DiSaia PJ, et al.: A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1989, 32:198–202.

    Article  PubMed  CAS  Google Scholar 

  32. Cohen C, Castro-Marin A, Deppe G, et al.: Chemotherapy of advanced or recurrent cervical cancer with platinum II: a preliminary report [abstract]. Proc ASCO 1978, 19:401.

    Google Scholar 

  33. Baker L: Cisplatin in treatment of cervical and endometrial cancer patients. In Cisplatin: Current Status and New Developments. Edited by Prestayko J, Crooke S, Carter S. New York: Academic Press; 1980:403–409.

    Google Scholar 

  34. Piver M, Barlow J, Xynos F: Adriamycin alone or in combination in 100 patients with carcinoma of the cervix or vagina. Am J Obstet Gynecol 1978, 131:311–313.

    PubMed  CAS  Google Scholar 

  35. Freeman R, Herson J, Wharton T, Rutledge F: Single agent chemotherapy for recurrent carcinoma of the cervix. Cancer Clin Trials 1980, 3:345–50.

    Google Scholar 

  36. Arseneau JC, Bundy B, Dolan T, et al.: Phase II study of Baker’s antifol in advanced squamous cell carcinoma of the cervix. Am J Clin Oncol 1982, 5:61–4.

    PubMed  CAS  Google Scholar 

  37. Malkasian G, Decker D, Jorgensen E: Chemotherapy of carcinoma of the cervix. Gynecol Oncol 1977, 5:109–120.

    Article  PubMed  Google Scholar 

  38. Takeuchi S, Noda K, Yakushiji M: Late phase II study of CPT-11, topoisomerse I inhibitor in advanced cervical carcinoma [abstract]. Proc ASCO 1992, 11:224.

    Google Scholar 

  39. Conroy JF, Lewis GC Jr, Blessing JA, et al.: ICRF-159 in patients with advanced squamous cell carcinoma of the uterine cervix. Am J Clin Oncol 1984, 7:131–133.

    Article  PubMed  CAS  Google Scholar 

  40. Asbury RF, Blessing JA, Mortel R, et al.: Aminothiadiazole in patients with advanced cervical carcinoma: a phase II study of the Gynecologic Oncology Group. Am J Clin Oncol 1987, 10:299–301.

    Article  PubMed  CAS  Google Scholar 

  41. Asbury RF, Blessing J, Soper J: A Gynecologic Oncology Group phase II study of amonafide in squamous cell carcinoma of the cervix. Am J Clin Oncol 1994, 17:125–128.

    Article  PubMed  CAS  Google Scholar 

  42. Bonomi P, Blessing JA, Sedlacek TV, et al.: Phase II trial of AMSA in patients with advanced or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Cancer Treat Rep 1983, 67:197–198.

    PubMed  CAS  Google Scholar 

  43. Omura G, Shingleton H, Creasman W, et al.: Chemotherapy of advanced gynecologic cancer with nitrosoureas: a randomized trial of CCNU and methyl CCNU in carcinoma of the cervix, corpus, vagina, vulva and tube. Cancer Treat Rep 1978, 62:833–835.

    PubMed  CAS  Google Scholar 

  44. Slayton RE, Blessing JA, Stehman FB, Malfetano J: Phase II clinical trial of diaziquone in the treatment of patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology study. Cancer Treat Rep 1986, 70:1127–1128.

    PubMed  CAS  Google Scholar 

  45. Roberts JA, Blessing JA, McGehee R, et al.: Phase II trial of dichloromethotrexate in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Cancer Treat Rep 1987, 71:1295–1296.

    PubMed  CAS  Google Scholar 

  46. Jacobs A, Blessing J, Munoz A: A phase II trial of didemnin B in advanced or recurrent cervical carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 1991, 44:268–270.

    Article  Google Scholar 

  47. Weiss GR, Liu PY, O’Sullivan J, et al.: A randomized phase II trial of trimetrexate or didemnin B for the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix: a Southwest Oncology Group trial. Gynecol Oncol 1992, 445:303–306.

    Article  Google Scholar 

  48. Muss, HB, Blessing JA, Malfetano J: Echinomycin in squamous-cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 1990, 13:191–193.

    Article  PubMed  CAS  Google Scholar 

  49. McGuire WP, Blessing JA, Yordan E, Beecham J: Phase II study of esorubicin in advanced or metastatic squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Invest New Drugs 1989, 7:235–238.

    PubMed  CAS  Google Scholar 

  50. Slayton RE, Creasman WT, Petty W, et al.: Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group study. Cancer Treat Rep 1979, 63:2089–2092.

    PubMed  CAS  Google Scholar 

  51. Manetta A, Blessing J, Mann W, Smith D: A phase II study of fazarabine in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Clin Oncol 1995, 18:156–157.

    Article  PubMed  CAS  Google Scholar 

  52. Look K, Blessing J, Muss H, et al.: 5-Flourouracil and leucovorin in the treatment of recurrent squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 1992, 15:497–499.

    Article  PubMed  CAS  Google Scholar 

  53. Look K, Blessing J, Gallup D, et al.: A phase II trial of 5-fluorouracil and high dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Clin Oncol 1992, 15:497–499.

    Article  PubMed  CAS  Google Scholar 

  54. Malfetano J, Blessing J, Homesley H, et al.: A phase II trial of gallium nitrate in advanced or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Invest New Drugs 1991, 9:109–111.

    Article  PubMed  CAS  Google Scholar 

  55. McGuire WP, Blessing JA, Hatch K, DiSaia PJ: A phase II study of CHIP in advanced squamous cell carcinoma of the cervix. Invest New Drugs 1986, 4:181–186.

    PubMed  CAS  Google Scholar 

  56. Thigpen JT, Ehrlich CE, Conroy J, Blessing JA: Phase II study of maytansine in the treatment of advanced or recurrent squamous cell carcinoma of the cervix. Am J Clin Oncol 1983, 6:427–430.

    Article  PubMed  CAS  Google Scholar 

  57. Sutton G, Blessing J, Gallup D, Homesley H: Phase II trial of menogaril in patients with squamous carcinoma of the cervix: a Gynecology Oncology Group study. Gynecol Oncol 1994, 52:229–231.

    Article  PubMed  CAS  Google Scholar 

  58. Look K, Blessing J, Williams L, et al.: A phase II trial of merebarone as salvage therapy for squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Clin Oncol 1995, 18:441–443.

    Article  PubMed  CAS  Google Scholar 

  59. Thigpen T, Blessing J, Gallup D, et al.: Phase II trial of mitomycin C in squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1995, 57:376–379.

    Article  PubMed  CAS  Google Scholar 

  60. Muss HB, Sutton GP, Bundy B, Hatch KD: Mitoxantrone in patients with advanced cervical carcinoma: a phase II study of the Gynecologic Oncology Group. Am J Clin Oncol 1985, 8:312–315.

    PubMed  CAS  Google Scholar 

  61. McGuire WP, Blessing JA, Hatch KD, Berman ML: Phase II study of N-methylformamide in patients with advanced squamous cancer of the cervix. Invest New Drugs 1990, 8:195–197.

    PubMed  Google Scholar 

  62. Muss HB, Bundy B, DiSaia PJ, et al.: PALA in advanced carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Am J Clin Oncol 1984, 7:741–744.

    Article  PubMed  CAS  Google Scholar 

  63. Thigpen JT, Blessing J, Homesley H, Acock L: Phase II trial of piperazinedione in the treatment of advanced or recurrent squamous cell carcinoma of the cervix. Am J Clin Oncol 1983, 6:423–426.

    Article  PubMed  CAS  Google Scholar 

  64. Muss, HB, Bundy BN, Yazigi R, Yordan E: Teniposide in squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group. Cancer Treat Rep 1987, 71:873–874.

    PubMed  CAS  Google Scholar 

  65. Feun L, Blessing J, Barrett R, Hanjani P: A phase II trial of tricyclic nucleoside phosphate (TCN-P) in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Clin Oncol 1993, 16:506–508.

    Article  PubMed  CAS  Google Scholar 

  66. Sutton GP, Blessing JA, Barnes W, Ball H: Phase II study of vinblastine in previously treated squamous carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Clin Oncol 1990, 13:470–471.

    Article  PubMed  CAS  Google Scholar 

  67. Slavik M, Muss H, Blessing JA: Phase II clinical study of Yoshi 864 in squamous cell carcinoma of the uterine cervix. Cancer Treat Rep 1983, 67:195–196.

    PubMed  CAS  Google Scholar 

  68. Bonomi P, Yordan E: Chemotherapy of cervical carcinoma. In Chemotherapy of Gynecologic Cancer, edn 2. Edited by Deppe G. New York: Wiley-Liss; 1990:121–153.

    Google Scholar 

  69. Kumar L, Bhargava V: Chemotherapy in recurrent and advanced cervical cancer. Gynecol Oncol 1991, 40:107–111.

    Article  PubMed  CAS  Google Scholar 

  70. Slayton RE, Blessing JA, Homesley HD: Phase II trial of etoposide in the management of advanced or recurrent nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Cancer Treat Rep 1984, 68:1513–1514.

    PubMed  CAS  Google Scholar 

  71. Stehman FB, Blessing JA, Homesley HD, et al.: Phase II evaluation of dianhydrogalactitol in the treatment of advanced non-squamous cell cervical carcinoma: a Gynecologic Oncology Group study. Invest New Drugs 1984, 2:331–333.

    Article  PubMed  CAS  Google Scholar 

  72. Homesley HD, Blessing JA, Berman M: ICRF-159 in patients with advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Clin Oncol 1986, 9:325–326.

    Article  PubMed  CAS  Google Scholar 

  73. Muss HB, Bundy BN, Homesley HD, Wilbanks G: Mitoxantrone in the treatment of advanced non-squamous cell carcinoma of the cervix. Invest New Drugs 1987, 5:199–202.

    Article  PubMed  CAS  Google Scholar 

  74. Slayton RE, Blessing JA, Rettenmaier M, Hall H: A phase II clinical trial of diaziquone in the treatment of patients with recurrent adenocarcinoma and adenosquamous carcinoma of the cervix: a Gynecologic Oncology Group study. Invest New Drugs 1989, 7:337–340.

    Article  PubMed  CAS  Google Scholar 

  75. Asbury RF, Blessing JA, DiSaia PJ, Malfetano J: Aminothiadiazole in patients with advanced nonsquamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Am J Clin Oncol 1989, 12:375–377.

    Article  PubMed  CAS  Google Scholar 

  76. Muss HB, Bundy BN, Given FT, Stehman FB: Teniposide in patients with non-squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 1990, 13:117–118.

    Article  PubMed  CAS  Google Scholar 

  77. Sutton G, Blessing J, Anderson B, et al.: Phase II trial of ifosfamide and mesna in patients with recurrent or advanced nonsquamous cell carcinoma of the cervix [abstract]. Proc ASCO 1990, 9:167.

    Google Scholar 

  78. Malfetano J, Blessing J, Homesley H: A phase II trial of gallium nitrate in nonsquamous cell carcinoma of the cervix. Am J Clin Oncol 1995, 18:495–497.

    Article  PubMed  CAS  Google Scholar 

  79. Mcguire WP, Blessing JA, Moore DH, et al.: Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group Study. J Clin Oncol 1996, 14:792–795.

    PubMed  CAS  Google Scholar 

  80. Wallace H, Hreshchyshyn M, Wilbanks G, et al.: Comparison of the therapeutic effect of adriamycin alone versus adriamycin plus vincristine versus adriamycin plus cyclophosphamide in the treatment of advanced carcinoma of the cervix. Cancer Treat Rep 1978, 62:1435–1441.

    PubMed  Google Scholar 

  81. Greenberg B, Kardinal C, Pajek T, Bateman J: Adriamycin versus adriamycin and bleomycin in advanced epidermoid carcinoma of the cervix. Cancer Treat Rep 1977, 61:1383–1384.

    PubMed  CAS  Google Scholar 

  82. Omura GA, Velez-Garcia E, Birch R, for the Southeastern Cancer Study Group: Phase II randomized study of doxorubicin, vincristrine, and 5-FU versus cyclophosphamide in advanced squamous cell carcinoma of the cervix. Cancer Treat Rep 1981, 65:901–903.

    PubMed  CAS  Google Scholar 

  83. Malkasian G, Decker D, Green S et al.: Treatment of recurrent and metastatic carcinoma of the cervix: comparison of doxorubicin with a combination of vincristine and 5-fluorouracil. Gynecol Oncol 1981, 11:235–239.

    Article  PubMed  Google Scholar 

  84. Brenner D: Combination chemotherapy of advanced cervix cancer. In Cervix Cancer. Edited by Surwit E, Alberts D. Boston: Martinus Nijhoff; 1987:137–160.

    Google Scholar 

  85. Jobson V, Homesley H, Muss H, et al.: Chemotherapy of advanced squamous carcinoma of the cervix: a phase I-II study of high-dose cisplatin and cyclophosphamide. Am J Clin Oncol 1984, 7:341–345.

    Article  PubMed  CAS  Google Scholar 

  86. Bezwoda WR, Nissenbaum M, Derman DP: Treatment of metastatic and recurrent cervix cancer with chemotherapy: a randomized trial comparing hydroxyurea with cisdiamminedichloroplatinum plus methotrexate. Med Pediatr Oncol 1986, 14:17–19.

    Article  PubMed  CAS  Google Scholar 

  87. Bonomi P, Yordan E, Blessing J: Phase I trial of cisplatin and razoxane in advanced squamous cell carcinoma of the cervix. Am J Clin Oncol 1988, 11:1–2.

    Article  PubMed  CAS  Google Scholar 

  88. Vogl S, Moukhtar M, Kaplan B: Chemotherapy for advanced cervical cancer with methotrexate, bleomycin, and cisdiamminedichloraplatinum. Cancer Treat Rep 1979, 63:1005–1006.

    PubMed  CAS  Google Scholar 

  89. Friedlander M, Kaye S, Sullivan A, et al.: Cervical carcinoma: a drug-responsive tumor-experience with combined cisplatin, vinblastine, and bleomycin therapy. Gynecol Oncol 1983, 16:275–281.

    Article  PubMed  CAS  Google Scholar 

  90. Chauvergne J, Heron J, Mayer F, et al.: Chemotherapy of cancers of the uterine cervix with a combination of bleomycin, mitomycin, cisplatin and etoposide. Bull Cancer 1993, 80:70–79.

    PubMed  CAS  Google Scholar 

  91. Weiss GR, Green S, Hannigan E, et al.: A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial. Gynecol Oncol 1990, 37:354–358.

    Article  PubMed  CAS  Google Scholar 

  92. Bonomi P, Blessing J, Ball H, et al.: A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1989, 34:357–359.

    Article  PubMed  CAS  Google Scholar 

  93. Chiara S, Consoli R, Falcone A, et al.: Cisplatin and 5-fluorouracil in advanced and recurrent cervical cancer. Tumori 1988, 74:471–474.

    PubMed  CAS  Google Scholar 

  94. Omura G, Hubbard J, Hatch K: Limited tolerance for high dose cisplatin plus doxorubicin after radiotherapy for female pelvic cancer: a Gynecologic Oncology Group pilot study. Am J Clin Oncol 1985, 8:347–349.

    PubMed  CAS  Google Scholar 

  95. Coleman R, Harper P, Gallagher C, et al.: A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix. Cancer Chemother Pharmacol 1986, 18:280–283.

    Article  PubMed  CAS  Google Scholar 

  96. Cervellino JC, Araujo CE, Sanchez O, et al.: Cisplatin and ifosfamide in patients with advanced squamous cell carcinoma of the uterine cervix. Acta Oncol 1995, 34:257–259.

    PubMed  CAS  Google Scholar 

  97. Kuhnle H, Meerpohl H, Eiermann W, et al.: Phase II study of carboplatin/ifosfamide in untreated advanced cervical cancer. Cancer Chemother Pharmacol 1990, 26:S33-S35.

    Article  PubMed  Google Scholar 

  98. Filtenborg TA, Hansen HH, Aage ES, Rorth M: A phase II study of ifosfamide, carboplatin and cisplatin in advanced and recurrent squamous cell carcinoma of the uterine cervix. Ann Oncol 1993, 4:485–488.

    PubMed  CAS  Google Scholar 

  99. Omura GA, Blessing JA, Vaccarello L, et al.: Randomized trial of cisplatin versus cisplatin plus mitolactor versus cisplatin plus ifosfamide in advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1997, 17:165–171. This multi-institution, phase III clinical trial conducted by the GOG established cisplatin and ifosfamide as the standard of care for women with advanced or recurrent carcinoma of the uterine cervix.

    Google Scholar 

  100. Kredentser DC: Etoposide, ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix. Gynecol Oncol 1991, 43:145–148.

    Article  PubMed  CAS  Google Scholar 

  101. Ramm K, Vergote I, Kaern J, Trope C: Bleomycin-ifosfamidecisplatinum (BIP) in pelvic recurrence of previously irradiated cervical carcinoma: a second look. Gynecol Oncol 1992, 46:203–207.

    Article  PubMed  CAS  Google Scholar 

  102. Tay SK, Lai FM, Soh LT, et al.: Combined chemotherapy using cisplatin, ifosfamide, and bleomycin (PIB) in the treatment of advanced and recurrent cervical carcinoma. Aust NZ J Obstet Gynecol 1993, 32:263–266.

    Article  Google Scholar 

  103. Buxton E, Meanwell C, Hilton C, et al.: Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer. J Natl Cancer Inst 1989, 81:359–361.

    Article  PubMed  CAS  Google Scholar 

  104. Murad AM, Triginelli SA, Ribalta JCL: Phase II trial of bleomycin, ifosfamide, and carboplatin in metastatic cervical cancer. J Clin Oncol 1994, 12:55–59.

    PubMed  CAS  Google Scholar 

  105. Rose PG, Blessing JA, Gershenson DM: Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study [abstract]. Proc Soc Gynecol Oncol 1997, 48.

  106. Muderspach LI, McGuire WP: A phase II trial of topotecan in patients with advanced squamous cell carcinoma of the cervix. Gynecol Oncol, in press.

  107. Petersen IA, Long HS, Abu-Ghazaleh, JS, et al.: North Central Cancer Treatment Group (NCCTG) study of neojadjuvant methotrexate, vincristine, cisplatin and adriamycin (MVCA) in locally advanced cervical carcinoma [abstract]. Proc ASCO 1995, 14:274.

    Google Scholar 

  108. Long HJ III, Cross WG, Wieand HS, et al.: Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina. Gynecol Oncol 1995, 57:235–239.

    Article  PubMed  Google Scholar 

  109. Murad AM, Medina L, Andrade CA, et al.: Phase II open label multicentric trial of MVAC—methotrexate (M), vinblastine (V), doxorubicin (A) and cisplatin (C) plus granulocyte colony simulating factor (Filgrastim) in advanced recurrent cervical carcinoma: final report [abstract]. Proc ASCO 1995, 14:276.

    Google Scholar 

  110. Papadimitriou CA, Dimopoulos MA, Giannakoulis N, et al.: A phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of metastatic carcinoma of the uterine cervix. Cancer 1997, 79:2391–2395.

    Article  PubMed  CAS  Google Scholar 

  111. Wilson TO: Neoadjuvant MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) chemotherapy for locally advanced or metatsatic cervical and vaginal cancer. In Adjuvant Therapy of Cancer VII. Edited by Salmon SE. Philadelphia: Lippincott; 1993: 366–371.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gynecologic Oncology, Ellis Fischel Cancer Center, 115 Business Loop 70 West, 65203, Columbia, MO, USA

    Jeffrey D. Bloss MD

Authors
  1. Jeffrey D. Bloss MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bloss, J.D. Chemotherapy for advanced or recurrent carcinoma of the cervix. Curr Oncol Rep 3, 33–40 (2001). https://doi.org/10.1007/s11912-001-0040-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-001-0040-5

Keywords

Search

Navigation